We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
-8.36%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.08%
AUM
$74.3B
AUM Growth
-$8.62B
(-10%)
Cap. Flow
-$532M
Cap. Flow
% of AUM
-0.72%
Top 10 Holdings %
Top 10 Hldgs %
52.32%
Holding
784
New
89
Increased
180
Reduced
401
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$556M |
| 2 |
NVIDIA
NVDA
|
+$117M |
| 3 |
Oracle
ORCL
|
+$104M |
| 4 |
Amazon
AMZN
|
+$79.8M |
| 5 |
Expedia Group
EXPE
|
+$77.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$161M |
| 2 |
Parker-Hannifin
PH
|
+$138M |
| 3 |
Cummins
CMI
|
+$94.8M |
| 4 |
Mettler-Toledo International
MTD
|
+$82.8M |
| 5 |
Home Depot
HD
|
+$77.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.44% |
| 2 | Communication Services | 20.45% |
| 3 | Consumer Discretionary | 17.53% |
| 4 | Healthcare | 11.66% |
| 5 | Industrials | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
MYR Group
MYRG
$5.15B
| $48M | 0.06% |
170,059
-14,194
| -8% | -$3.69M |
|
102
TD Synnex
SNX
$20.2B
| $47.5M | 0.06% |
281,818
+10,147
| +4% | +$1.6M |
|
103
Doximity
DOCS
$3.82B
| $47.5M | 0.06% |
2,036,984
+6,642
| +0.3% | +$207K |
|
104
FB Financial Corp
FBK
$3B
| $47.4M | 0.06% |
912,604
-62,111
| -6% | -$3.49M |
|
105
Mercury Systems
MRCY
$5.76B
| $47.1M | 0.06% |
645,932
-205,885
| -24% | -$17.9M |
|
106
Silicon Laboratories
SLAB
$7.15B
| $46.5M | 0.06% |
223,342
-240,723
| -52% | -$44.1M |
|
107
CRISPR Therapeutics
CRSP
$4.77B
| $46.1M | 0.06% |
968,135
+68,804
| +8% | +$3.63M |
|
108
Glaukos
GKOS
$9.9B
| $45.4M | 0.06% |
421,240
-26,565
| -6% | -$2.99M |
|
109
UnitedHealth
UNH
$383B
| $45.1M | 0.06% |
166,589
-9,760
| -6% | -$2.91M |
|
110
Veeva Systems
VEEV
$32.7B
| $44.9M | 0.06% |
255,396
+7,955
| +3% | +$1.56M |
|
111
VSE Corp
VSEC
$5.37B
| $44.7M | 0.06% |
242,376
-11,660
| -5% | -$2.37M |
|
112
OneSpaWorld
OSW
$2.64B
| $44.4M | 0.06% |
1,934,839
-161,429
| -8% | -$3.43M |
|
113
Mirum Pharmaceuticals
MIRM
$6.87B
| $43.9M | 0.06% |
475,324
-39,657
| -8% | -$3.73M |
|
114
Dana Inc
DAN
$2.91B
| $43.8M | 0.06% |
1,302,384
-289,384
| -18% | -$9.05M |
|
115
McGrath RentCorp
MGRC
$2.82B
| $43.7M | 0.06% |
396,563
+8,776
| +2% | +$975K |
|
116
iRhythm Holdings
IRTC
$3.91B
| $43.4M | 0.06% |
367,894
-24,183
| -6% | -$3.49M |
|
117
Axsome Therapeutics
AXSM
$12.1B
| $43.4M | 0.06% |
256,625
-58,766
| -19% | -$10.2M |
|
118
The Ensign Group
ENSG
$10.4B
| $41.5M | 0.06% |
206,125
-17,199
| -8% | -$3.36M |
|
119
PJT Partners
PJT
$4.33B
| $41.3M | 0.06% |
295,584
-24,661
| -8% | -$3.88M |
|
120
Calix
CALX
$2.22B
| $41.2M | 0.06% |
840,197
+50,305
| +6% | +$2.64M |
|
121
Piper Sandler
PIPR
$5.15B
| $41.1M | 0.06% |
536,352
-44,756
| -8% | -$3.67M |
|
122
Extreme Networks
EXTR
$3.9B
| $41M | 0.06% |
2,715,683
+227,535
| +9% | +$3.4M |
|
123
Rhythm Pharmaceuticals
RYTM
$7.25B
| $40.4M | 0.05% |
465,102
-38,799
| -8% | -$3.77M |
|
124
Viper Energy
VNOM
$8.48B
| $40.4M | 0.05% |
859,421
+18,860
| +2% | +$809K |
|
125
BioMarin Pharmaceuticals
BMRN
$11.7B
| $40.3M | 0.05% |
713,795
+2,024
| +0.3% | +$118K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q1 2026 Portfolio in Review
As of Q1 2026, Loomis, Sayles & Company held 784 positions worth $74.3B, down 10% from $83B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Loomis, Sayles & Company's Q1 2026 filing shows 89 new, 180 increased, 401 reduced and 66 closed positions. Its largest new stake was PTC Therapeutics: 493,603 shares worth $33.6M. The largest sale was Illumina, an estimated $161M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 28% a quarter earlier, followed by Communication Services and Consumer Discretionary.
- Loomis, Sayles & Company's largest Q1 2026 buy was PTC Therapeutics: 493,603 shares worth $33.6M.
- Loomis, Sayles & Company added most to Booking.com in Q1 2026, an estimated $556M increase.
- Loomis, Sayles & Company's biggest Q1 2026 reduction was Illumina, cutting an estimated $161M.
- Loomis, Sayles & Company fully exited Wave Life Sciences in Q1 2026, selling an estimated $34.7M.
- Loomis, Sayles & Company's ten largest holdings make up 52% of its $74.3B portfolio in Q1 2026.
- Loomis, Sayles & Company opened 89 new positions and closed 66 in Q1 2026.
- Loomis, Sayles & Company's portfolio value fell 10% quarter-over-quarter to $74.3B.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.